Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches
Abstract
1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Gundem, G.; Van Loo, P.; Kremeyer, B.; Alexandrov, L.B.; Tubio, J.M.; Papaemmanuil, E.; Brewer, D.S.; Kallio, H.M.; Högnäs, G.; Annala, M. The evolutionary history of lethal metastatic prostate cancer. Nature 2015, 520, 353–357. [Google Scholar] [CrossRef] [PubMed]
- Phillips, R.; Shi, W.Y.; Deek, M.; Radwan, N.; Lim, S.J.; Antonarakis, E.S.; Rowe, S.P.; Ross, A.E.; Gorin, M.A.; Deville, C.; et al. Outcomes of observation vs stereotactc ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020, 6, 650–659. [Google Scholar] [CrossRef] [PubMed]
- Fendler, W.P.; Calais, J.; Eiber, M.; Flavell, R.R.; Mishoe, A.; Feng, F.Y.; Nguyen, H.G.; Reiter, R.E.; Rettig, M.B.; Okamoto, S.; et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: A prospective single-arm clinical trial. JAMA Oncol. 2019, 5, 856–863. [Google Scholar] [CrossRef] [PubMed]
- Morris, M.J.; Rowe, S.P.; Gorin, M.A.; Saperstein, L.; Pouliot, F.; Josephson, D.; Wong, J.Y.; Pantel, A.R.; Cho, S.Y.; Gage, K.L.; et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase III multicenter study. Clin. Cancer Res. 2021, 27, 3674–3682. [Google Scholar] [CrossRef] [PubMed]
- Sobol, I.; Zaid, H.B.; Haloi, R.; Mynderse, L.A.; Froemming, A.T.; Lowe, V.J.; Davis, B.J.; Kwon, E.D.; Karnes, R.J. Contemporary mapping of post-prsotatectomy prostate cancer relapse with 11C-choline positron emission tomorgraphy and multiparametric magnetic resonance imaging. J. Urol. 2017, 197, 129–134. [Google Scholar] [CrossRef] [PubMed]
- Siva, S.; Bressel, M.; Murphy, D.C.; Shaw, M.; Chander, S.; Violet, J.; Tai, K.H.; Udovicich, C.; Lim, A.; Selbie, L. Steroetactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: A prospective clinical trial. Eur. Urol. 2018, 74, 455–462. [Google Scholar] [CrossRef] [PubMed]
- Ost, P.; Reynders, D.; Decaestecker, K.; Fonteyne, V.; Lumen, N.; De Bruycker, A.; Lambert, B.; Delrue, L.; Bultijnck, R.; Claeys, T.; et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer: A prospective randomized multicenter phase II trial. J. Clin. Oncol. 2018, 36, 446–453. [Google Scholar] [CrossRef] [PubMed]
- Karmakar, A.; Kumtakar, A.; Sehgal, H.; Kumar, S.; Kalyanpur, A. Interobserver Variation in Response Evaluation Criteria in Solid Tumors 1.1. Acad Radiol. 2019, 26, 489–501. [Google Scholar] [CrossRef] [PubMed]
- Johnstone, P.A.; Tarman, G.H.; Riffenburgh, R.; Rohde, D.C.; Puckett, M.L.; Kane, C.J. Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients. Urol. Oncol. 1997, 3, 108–112. [Google Scholar] [CrossRef] [PubMed]
- Sasikumar, A.; Joy, A.; Nanabala, R.; Pillai, M.R.A.; Hari, T.A. 68Ga-PSMA PET/CT false-positive tracer uptake in paget disease. Clin. Nucl. Med. 2016, 41, e454–e455. [Google Scholar] [CrossRef] [PubMed]
- Bucknor, M.D.; Lichtensztajn, D.Y.; Lin, T.K.; Borno, H.T.; Gomez, S.L.; Hope, T.A. Disparities in PET imaging for prostate cancer at a Tertiary Academic Medical Center. J. Nucl. Med. 2021, 62, 695–699. [Google Scholar] [CrossRef] [PubMed]
- Kehl, K.L.; Landrum, M.B.; Kahn, K.L.; Gray, S.W.; Chen, A.B.; Keating, N.L. Tumor board participation among physicians caring for patients with lung or colorectal cancer. J. Oncol. Pract. 2015, 11, e267–e278. [Google Scholar] [CrossRef] [PubMed]
- Wondergem, M.; van der Zant, F.M.; Knol, R.J.J.; Burgers, A.M.G.; Bos, S.D.; DeJong, I.J.; Pruim, J. 99mTc-HDP bone scintigraphy and 18F-sodium fluoride PET/CT in primary staging of patients with prostate cancer. World J. Urol. 2018, 36, 27–34. [Google Scholar] [CrossRef] [PubMed]
- Vargas, H.A.; Schor-Bardach, R.; Long, N.; Kirzner, A.N.; Cunningham, J.D.; Goldman, D.A.; Moskowitz, C.S.; Sosa, R.E.; Sala, E.; Panicek, D.M.; et al. Prostate cancer bone metastases on staging prostate MRI: Prevalence and clinical features associated with their diagnosis. Abdom. Radiol. 2017, 42, 271–277. [Google Scholar] [CrossRef] [PubMed]
- McKay, R.R.; Zukotynski, K.A.; Werner, L.; Voznesensky, O.; Wu, J.S.; Smith, S.E.; Jiang, Z.; Melnick, K.; Yuan, X.; Kantoff, P.W.; et al. Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration resistant prostate cancer. Prostate Cancer Prost. Dis 2014, 17, 325–331. [Google Scholar] [CrossRef] [PubMed]
Eligible (n = 19) | Ineligible—Too Many Metastases (n = 6) | Ineligible—Not Metastatic (n = 13) | p Value ^ | |
---|---|---|---|---|
Median PSA * (range) | 3.28 (0.4–45.5) | 10.45 (3.7–26.3) | 2.7 (0.2–34.5) | Many p = 0.057 Few p = 1.0 |
Primary untreated | 18.1 (9.1–45.5) | 8.9 (4.6–13.1) | 13.7 (4.8–34.5) | |
Primary treated | 1.7 (0.4–27.5) | 12 (3.7–26.3) | 1.174 (0.2–2.3) | |
Gleason grade group N (%) | ||||
1 | 3 (16%) | 0 | 1 (8%) | p = 0.17 |
2–3 | 8 (42%) | 4 (67%) | 4 (31%) | p = 0.37 |
4–5 | 8 (42%) | 2 (33%) | 8 (61%) | p = 0.14 |
Imaging modalities | ||||
MRI | 10 | 1 | 7 | |
PET (fluciclovine) | 7 | 4 | 5 | |
PET (PSMA) | 3 | 0 | 1 |
Study | # Metastases | Other Restrictions | Imaging Used to Define # of Metastases |
---|---|---|---|
POP-STAR [6] | 1–3 | Bone or LN only | [18F]-NaF PET/CT |
ORIOLE [2] | 1–3 | Asymptomatic, arose in the prior 6 months, ≤5 cm in long axis or ≤250 cm2 | Conventional imaging |
STOMP [7] | 1–3 | Extracranial, negative MRI or biopsy of prostate bed even if choline PET negative in prostate bed | [11C]Choline PET |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dorff, T.B.; Kasparian, S.; Garg, N.; Liu, S.; Pal, S.K.; Wong, J.; Dandapani, S. Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches. J. Clin. Med. 2023, 12, 2011. https://doi.org/10.3390/jcm12052011
Dorff TB, Kasparian S, Garg N, Liu S, Pal SK, Wong J, Dandapani S. Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches. Journal of Clinical Medicine. 2023; 12(5):2011. https://doi.org/10.3390/jcm12052011
Chicago/Turabian StyleDorff, Tanya Barauskas, Saro Kasparian, Natasha Garg, Sandy Liu, Sumanta Kumar Pal, Jeffrey Wong, and Savita Dandapani. 2023. "Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches" Journal of Clinical Medicine 12, no. 5: 2011. https://doi.org/10.3390/jcm12052011
APA StyleDorff, T. B., Kasparian, S., Garg, N., Liu, S., Pal, S. K., Wong, J., & Dandapani, S. (2023). Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches. Journal of Clinical Medicine, 12(5), 2011. https://doi.org/10.3390/jcm12052011